Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

Summary

The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.

Conditions

• Bladder Cancer

Interventions

BIOLOGICAL

Mycobacterium w

Immunomodulator

Sponsors & Collaborators

• Cadila Pharnmaceuticals

  lead INDUSTRY

Principal Investigators

• Mahesh Desai, MD · Muljibhai Patel Urological Hospital

• Amillal Bhat, MD · S P Medical College & AG of Hospital

• Sushil Bhatia, MD · Choithram Hospital and Research Centre

• Kim Mammen, MD · Christian Medical College, Vellore, India

• Ketan Rajyaguru, MD · Siddhi Vinayak Hospital

• Gaurang Gandhi, MD · Gandhi Urocare

• Kapil Thakkar, MD · Excel Hospital

• B. R. Shrivastav, MD · Cancer Hospital & Research Institute

• Anup Kundu, MD · IPGMER, S.S.K.M. Hospital

• Jitendra Amlani, MD · Urocare Hospital

• Rasesh Desai, MD · Desai Urological and Maternity Hospital

• N. K. Mohanty, MD · V. M. Medical College and Safdarjang hospital

• Shrawan K. Singh, MD · Post Graduate Institute of Medical Education and Research, Chandigarh

• Ketan Shukla, MD · Aarogyam Speciality Hospital

• Krishna Moorhty, MD · Lourdes hospital

• Rajeev Sood, MD · Dr. Ram Manohar Lohia Hospital and PGIMER

• Purshottam K. Puri, MD · Indira Gandhi Medical College, Shimla

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-10-31

Primary Completion

2011-07-31

Completion

2011-07-31

Countries

• India

Study Locations